Biomedical knowledge graphs driving new target identification and novel drug discovery
Pan Dou, Xiaobo Yang, Yuling Jiang, Xiaowei Xie, Xiaoju Geng, He Huang, Honglin Li, Shiliang Li
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Biomedical knowledge graphs (KGs) provide a structured and traceable framework for target-oriented, AI-assisted drug discovery. By linking genes, proteins, diseases, phenotypes, compounds, pathways, assays, structures, adverse events, and clinical evidence, biomedical KGs can partially mitigate evidence fragmentation and support hypothesis generation across molecular, cellular, and clinical levels. This review summarizes how biomedical KGs are constructed, reasoned over, evaluated, and translated into practical drug-discovery tasks. We first outline major data resources, entity and relation extraction, knowledge fusion, quality control, and large language model-assisted KG construction, with emphasis on ontology grounding, evidence tracing and hallucination control. We then compare key KG reasoning paradigms, including symbolic rule-based reasoning, representation learning, path- and subgraph-aware reasoning, graph Transformer models, and KG-LLM hybrid reasoning. Their strengths and limitations are discussed in relation to interpretability, scalability, leakage risk, benchmark bias, and prospective validation. We further highlight the need to incorporate three-dimensional structural evidence, including protein structures, binding pockets, variants, conformational states, and ligand compatibility, so that graph-based relevance can be connected with chemical tractability. Finally, we discuss applications of biomedical KGs in target prioritization, druggability assessment, mechanism interpretation, drug-target interaction prediction, molecular generation, lead optimization, ADMET and safety assessment, drug repurposing, combination therapy, biomarker discovery, precision medicine, and drug-resistance modeling. Current limitations include heterogeneous data quality, incomplete causal evidence, static graph representations, privacy constraints, and insufficient experimental or clinical validation. Overall, biomedical KGs should be viewed as evidence-integration and prioritization engines rather than automatic proof-generating systems for drug discovery, guiding rigorous, iterative, and experimentally grounded translational decisions.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Computational Drug Discovery Methods
Biomedical Text Mining and Ontologies · Bioinformatics and Genomic Networks
参考文献 198
此处列出前 3 条
引用本文 1
按被引量排序,此处列出前 3 条